Application segmentation dissects the Cadonilimab Injection market according to therapeutic endpoints, revealing how each clinical use drives revenue. The dominant cervical cancer cohort accounts for roughly 45 % of projected sales, reflecting regulatory approval in multiple jurisdictions and a sizable patient pool exceeding 600,000 new cases annually. Endometrial cancer follows with an estimated 30 % share, supported by phase III data that position Cadonilimab as a second‑line option for high‑risk histologies. A broader other oncology segment—encompassing ovarian, head‑and‑neck, and triple‑negative breast cancers—contributes about 15 % of the market, primarily through off‑label use and early‑phase trials. Finally, emerging indications such as microsatellite‑instability‑high tumors and combination immunotherapy regimens represent the remaining 10 %, indicating future growth potential. Collectively, these application categories define the overall Cadonilimab Injection market size and provide a clear framework for the Cadonilimab Injection segmentation analysis. Pricing pressures, reimbursement pathways, and competitive biosimilar entrants are expected to modulate the relative contribution of each application, underscoring the importance of granular segmentation for strategic forecasting.
